Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017144708 - ANTI-VIRAL DRUG

Publication Number WO/2017/144708
Publication Date 31.08.2017
International Application No. PCT/EP2017/054422
International Filing Date 24.02.2017
IPC
A61K 31/53 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
C07D 253/10 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
253Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/166
08condensed with carbocyclic rings or ring systems
10Condensed 1,2,4-triazines; Hydrogenated condensed 1,2,4-triazines
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 31/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
53having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07D 249/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
249Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
02not condensed with other rings
081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
10with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
14Nitrogen atoms
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Y02A 50/30
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection, e.g. against extreme weather
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applicants
  • DORING INTERNATIONAL GMBH [CH]/[CH]
Inventors
  • SOROKIN, Pavel Vladimirovich
  • THORNE, David Edmund
Agents
  • GEVERS PATENTS
Priority Data
16157237.524.02.2016EP
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-VIRAL DRUG
(FR) MÉDICAMENT ANTIVIRAL
Abstract
(EN) An antiviral compound for use in the treatment of negative-sense, single-stranded RNA [herein after ssRNA] virus infections different from the Influenza A and Influenza B virus infections wherein said antiviral compound is of general formula (I) ) [compound (A), herein after] or a pharmaceutically acceptable salt thereof wherein - R1 is selected from an alkyl group having 1 to 12 carbon atoms which is optionally substituted by a halogen atom or hydroxyl group, a cycloalkyl group having 3 to 12 carbon atoms which is optionally substituted by a halogen atom or hydroxyl group, an aryl group, an alkylaryl group, or a cycloheteroalkyl group having 3 to 12 carbon atoms, preferably an alkyl group having 1 to 8 carbon atoms optionally substituted by a halogen atom or hydroxyl group, a cycloalkyl group having 3 to 6 carbon atoms which is optionally substituted by a halogen atom or hydroxyl group, a phenyl, a benzyl, a morpholine, or an imidazolyl, more preferably an alkyl group having 1 to 4 carbon atoms, a cyclohexyl, a phenyl or a benzyl.
(FR) L'invention concerne un composé antiviral destiné à être utilisé pour le traitement d'infections à virus à ARN simple brin (désigné ci-après ARNss) de sens négatif autres que les infections à Influenzavirus A et Influenzavirus B, ledit composé antiviral étant de formule générale (I) [composé (A), ci-après] ou un sel pharmaceutiquement acceptable correspondant ; dans la formule (I), R1 est choisi parmi un groupe alkyle comportant 1 à 12 atomes de carbone qui est éventuellement substitué par un atome d'halogène ou un groupe hydroxyle, un groupe cycloalkyle comportant 3 à 12 atomes de carbone qui est éventuellement substitué par un atome d'halogène ou un groupe hydroxyle, un groupe aryle, un groupe alkylaryle ou un groupe cyclohétéroalkyle comportant 3 à 12 atomes de carbone, de préférence un groupe alkyle comportant 1 à 8 atomes de carbone éventuellement substitué par un atome d'halogène ou un groupe hydroxyle, un groupe cycloalkyle comportant 3 à 6 atomes de carbone qui est éventuellement substitué par un atome d'halogène ou un groupe hydroxyle, un phényle, un benzyle, une morpholine ou un imidazolyle, plus préférentiellement un groupe alkyle comportant 1 à 4 atomes de carbone, un cyclohexyle, un phényle ou un benzyle.
Related patent documents
Latest bibliographic data on file with the International Bureau